Login
$OCGN
$0.77 -$0.06 (7.01%) Live

$OCGN SEC Filings

Filed On Filing
10 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) ...

06 Nov 2026 DEFA14A
06 Nov 2026 DEFA14A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Received Provisional Approval and Priority Designation for OCU400 in The Bahamas

15 Oct 2026 8-K: Regulation FD Disclosure

Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally

15 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

13 Oct 2026 Form 4: Musunuri Shankar, Director

Sold 525,991 shares ($500K)

09 Oct 2026 144
06 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 5, 2026, Ocugen, Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”) virtually, which had been adjourned on September 21, 2026 solely with respect to the proposal to approve the adoption...

23 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 21, 2026, Ocugen, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually, which was adjourned to October 5, 2026 solely with respect to the proposal to approve the adoption of an amendm...

11 Sep 2026 Form 4: Musunuri Shankar, Director

Sold 525,991 shares ($589K)

09 Sep 2026 144
08 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally

14 Aug 2026 DEFA14A
13 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter

30 Jul 2026 DEFA 14A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support